Company intelligence / Profile preview
UTILITY therapeutics
Altrincham, England, United Kingdomutilitytherapeutics.com ↗
- Ownership
- Private
- Development stage
- NDA
01
Overview
FDA approved PIVYA (pivmecillinam) for treatment of female adults with uncomplicated UTIs on April 25, 2024. Clinical trials showed 62% of 137 subjects achieved composite response compared to 10% with placebo. In another trial, 72% of 127 subjects achieved composite response compared to 76% with a comparator drug. In a third trial, 66% of 105 subjects achieved composite response compared to 22% with ibuprofen[5].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculesAntibiotics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
LEO Pharma A/S (license agreement for US rights to mecillinam and pivmecillinam)[6]
Beyond the preview
Go deeper on UTILITY therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UTILITY therapeutics.